Patents Assigned to NeoTX Therapeutics Ltd. - Justia Patents Search

Patents Assigned to NeoTX Therapeutics Ltd.

Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy

Patent number: 11607452

Abstract: The invention provides methods or compositions for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with a PD-1 inhibitor.

Type: Grant

Filed: December 11, 2019

Date of Patent: March 21, 2023

Assignee: NeoTX Therapeutics Ltd.

Inventors: Asher Nathan, Michal Shahar
Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy

Patent number: 11202829

Abstract: Provided is a method for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with a PD-1 inhibitor.

Type: Grant

Filed: May 14, 2019

Date of Patent: December 21, 2021

Assignee: NeoTX Therapeutics Ltd.

Inventors: Asher Nathan, Michal Shahar
Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy

Patent number: 10314910

Abstract: Provided is a method for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with an immunopotentiator (for example, a PD-1 inhibitor).

Type: Grant

Filed: January 10, 2017

Date of Patent: June 11, 2019

Assignee: NeoTX Therapeutics Ltd.

Inventors: Asher Nathan, Michal Shahar